Fintel reports that on November 11, 2025, Morgan Stanley maintained coverage of Personalis (NasdaqGM:PSNL) with a Equal-Weight recommendation.
Analyst Price Forecast Suggests 10.01% Downside
As of November 9, 2025, the average one-year price target for Personalis is $7.59/share. The forecasts range from a low of $5.05 to a high of $11.55. The average price target represents a decrease of 10.01% from its latest reported closing price of $8.43 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Personalis is 129MM, an increase of 86.82%. The projected annual non-GAAP EPS is -2.23.
What is the Fund Sentiment?
There are 237 funds or institutions reporting positions in Personalis. This is an increase of 49 owner(s) or 26.06% in the last quarter. Average portfolio weight of all funds dedicated to PSNL is 0.39%, an increase of 1.57%. Total shares owned by institutions increased in the last three months by 8.79% to 73,084K shares. 
The put/call ratio of PSNL is 0.22, indicating a bullish outlook.
What are Other Shareholders Doing?
Merck holds 14,045K shares representing 15.82% ownership of the company. No change in the last quarter.
Lightspeed Management Company, L.L.C. holds 8,161K shares representing 9.19% ownership of the company. No change in the last quarter.
ARK Investment Management holds 7,108K shares representing 8.00% ownership of the company. In its prior filing, the firm reported owning 7,188K shares , representing a decrease of 1.13%. The firm increased its portfolio allocation in PSNL by 35.37% over the last quarter.
ARKG - ARK Genomic Revolution ETF holds 7,003K shares representing 7.89% ownership of the company. In its prior filing, the firm reported owning 6,773K shares , representing an increase of 3.28%. The firm increased its portfolio allocation in PSNL by 41.31% over the last quarter.
AIGH Capital Management holds 3,892K shares representing 4.38% ownership of the company. In its prior filing, the firm reported owning 3,724K shares , representing an increase of 4.32%. The firm decreased its portfolio allocation in PSNL by 34.92% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
